Collaborative Consult: Cases, Patient Reflection, and Discussions – What’s New in Pediatric Atopic Dermatitis – Tweetorial Evaluation (ID: i830-15) Survey

Question Title

* 1. How many years have you been in practice? 

>21

11-20

1-10

Question Title

* 2. How many patients with pediatric atopic dermatitis do you manage per week? 

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

* 3. Please select the option that best describes your practice setting.

Academic medical center

Community medical center

VA, DOD, or other government

Managed care

Research

Pharmaceutical industry

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with atopic dermatitis in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 5. After participating in this activity, do you intend to incorporate newly FDA-approved therapies into your clinical practice for patients with moderate-to-severe atopic dermatitis aged ≥6 months?

Yes, immediately

Undecided

Will wait to hear from colleagues regarding experience with these agents in clinical practice

Will wait until additional clinical trial data becomes available

Will not

Question Title

* 6. How committed are you to making changes in your practice based on your participation in this activity? 

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

If not committed or do not plan to make changes, please indicate reason

Question Title

* 7. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information I can apply to my area of practice

I need more information before I can change my practice

My practice is already consistent with the information presented

This activity will not change my practice

Question Title

* 8. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Increased understanding of the pathophysiologic differences of AD between pediatric & adult patients

Increased knowledge of the immune dysregulation and pathogenesis in pediatric AD

Greater awareness of the efficacy and safety of recently approved agents for the treatment of AD

Improved understanding of emerging therapies' potential for the treatment of AD

Increased awareness of the limitations of current guidelines and the need for updated guidelines

Improved ability to incorporate effective multidisciplinary management strategies

Better able to recognize when to switch treatment regimens

Improved understanding of validated measures to assess disease severity and monitor AD progression

Improved ability to incorporate shared decision making and patient education in clinical practice to improve patient outcomes

Better understanding of when to refer patient to a specialist

Question Title

* 9. What barriers do you see to making changes in your practice? Please select all that apply.

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Conflicting guidelines or evidence

Patient compliance and/or patient resource barriers

Other (please specify)

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating:
Strongly agree, Agree, Neutral, Disagree, Strongly disagree

After participating in today’s activity, I am now better able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Describe the immunopathogenesis of AD	Describe the immunopathogenesis of AD Strongly agree	Describe the immunopathogenesis of AD Agree	Describe the immunopathogenesis of AD Neutral	Describe the immunopathogenesis of AD Disagree	Describe the immunopathogenesis of AD Strongly disagree
Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD	Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Strongly agree	Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Agree	Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Neutral	Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Disagree	Summarize current clinical trial data on the safety and efficacy of new and emerging therapies for pediatric AD Strongly disagree
Apply evidence-based guideline recommendations to the treatment of pediatric AD	Apply evidence-based guideline recommendations to the treatment of pediatric AD Strongly agree	Apply evidence-based guideline recommendations to the treatment of pediatric AD Agree	Apply evidence-based guideline recommendations to the treatment of pediatric AD Neutral	Apply evidence-based guideline recommendations to the treatment of pediatric AD Disagree	Apply evidence-based guideline recommendations to the treatment of pediatric AD Strongly disagree

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating.
Strongly agree, Agree, Neutral, Disagree, Strongly disagree

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Faculty for this activity was effective	Faculty for this activity was effective Strongly agree	Faculty for this activity was effective Agree	Faculty for this activity was effective Neutral	Faculty for this activity was effective Disagree	Faculty for this activity was effective Strongly disagree
Content was scientifically rigorous and evidence based	Content was scientifically rigorous and evidence based Strongly agree	Content was scientifically rigorous and evidence based Agree	Content was scientifically rigorous and evidence based Neutral	Content was scientifically rigorous and evidence based Disagree	Content was scientifically rigorous and evidence based Strongly disagree
Avoided commercial bias or influence	Avoided commercial bias or influence Strongly agree	Avoided commercial bias or influence Agree	Avoided commercial bias or influence Neutral	Avoided commercial bias or influence Disagree	Avoided commercial bias or influence Strongly disagree

Question Title

* 12. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for atopic dermatitis or related disease state:

Question Title

* 1. How many years have you been in practice?

Question Title

* 2. How many patients with pediatric atopic dermatitis do you manage per week?

Question Title

* 3. Please select the option that best describes your practice setting.

Question Title

* 4. After participating in this activity, how confident are you in the management of patients with atopic dermatitis in your practice?

Question Title

* 5. After participating in this activity, do you intend to incorporate newly FDA-approved therapies into your clinical practice for patients with moderate-to-severe atopic dermatitis aged ≥6 months?

Question Title

* 6. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 7. Which of the following best describes the impact of this activity on your performance?

Question Title

* 8. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.

Question Title

* 9. What barriers do you see to making changes in your practice? Please select all that apply.

Question Title

* 10. Please rate your level of agreement by checking the appropriate rating:Strongly agree, Agree, Neutral, Disagree, Strongly disagreeAfter participating in today’s activity, I am now better able to:

Question Title

* 11. Please rate your level of agreement by checking the appropriate rating. Strongly agree, Agree, Neutral, Disagree, Strongly disagree

Question Title

* 12. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for atopic dermatitis or related disease state:

* 1. How many years have you been in practice? 

* 2. How many patients with pediatric atopic dermatitis do you manage per week? 

* 6. How committed are you to making changes in your practice based on your participation in this activity? 

* 10. Please rate your level of agreement by checking the appropriate rating:
Strongly agree, Agree, Neutral, Disagree, Strongly disagree

After participating in today’s activity, I am now better able to:

* 11. Please rate your level of agreement by checking the appropriate rating.
Strongly agree, Agree, Neutral, Disagree, Strongly disagree